ANTABIO raises € 7.3M Series A Financing to Develop Novel Treatments against Drug-Resistant Gram-negative infections16 October 2017
The Series A Complements Recent CARB-X Grant of up to $8,9 Million Labège, 16 October 2017. Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today the completion of a €7.3M series A financing with subscriptions from investment funds iXO Private Equity, IRDI [...]
iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion et les investisseurs historiques d’Antabio participent à cette augmentation de capital. Labège, le 16 Octobre 2017. Antabio SAS, société biopharmaceutique spécialisée dans la lutte contre les infections résistantes aux antibiotiques, annonce aujourd’hui avoir réalisé une tour de financement série A d’un montant de 7,3 millions [...]
ANTABIO awarded up to $8.9M from CARB-X to accelerate the development of its new treatment for chronic infections in Cystic Fibrosis patients25 July 2017
Labège, 25 July 2017. Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today that it has been awarded up to $8.9 million non-dilutive funding from CARB-X, the world’s largest public-private partnership devoted to antibacterial R&D. Antabio was selected by CARB-X from a [...]
ANTABIO reçoit le soutien du consortium mondial CARB-X pour financer le développement de ses nouveaux traitements contre les infections chroniques résistantes aux antibiotiques25 July 2017
Labège, le 25 Juillet 2017. Antabio SAS, société biopharmaceutique spécialisée dans la lutte contre les infections résistantes aux antibiotiques, annonce qu’elle a obtenu le soutien du consortium mondial CARB-X et qu’elle recevra à ce titre un financement non-dilutif pouvant atteindre 8 millions d’euros pour soutenir ses programmes de recherche et [...]
- 19 January 2017
Labège, 19 January 2017. Antabio’s CEO Marc Lemonnier has been elected at the Board of Directors of the BEAM Alliance (Biopharmaceutical companies from Europe innovating in Anti-Microbial resistance research) further to the alliance’s Extraordinary General Assembly held in Paris on 20 December 2016. The BEAM Alliance represents European biopharmaceutical companies involved [...]
- 12 January 2017
Labège, 12th Jan 2017. Antabio announces that it will be presenting at the 19th annual Superbugs & Superdrugs conference in London (20th-21st March 2017) Expanding horizons on the growing threat of anti-microbial resistance for almost two decades, this is the flagship show in the global Superbugs portfolio of events and will [...]
- 11 May 2016
Labège, 11th May 2016. Antabio announces that it has been selected as one of the ten companies that will be presenting at the BIO 2016 Global Workshop for Novel Anti-Infectives. Organized by the Innovative Medicines Initiative (IMI), The Wellcome Trust-funded Community For Open Antimicrobial Drug Discovery (CO-ADD) and the IMI [...]
Labège, 14th April 2016. Antabio announced today that the company has received the BIOVISION Investment Conference 2016 Award in the biotech category. The BIOVISION Investor Conference was created to accelerate the fundraising process of Biotech, Medtech, e-health and environmental health start-ups by putting them in direct contact with potential business [...]
- 18 February 2016
Labège, France— February 18, 2016 — Dr. Marc Lemonnier, co-founder and CEO of Antabio, will participate in a BioPharma Dealmakers webcast, sponsored in part by Antabio, featuring five companies innovating antibiotic technologies. The webcast, part of the BioPharma Dealmakers series, is scheduled for 8AM PST, 11AM EST, 4PM GMT, 5PM [...]
Antabio signs the Industry call for new antimicrobial business models presented at the World Economic Forum, Davos21 January 2016
On January 21, 2016, the Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance was launched at an event at the World Economic Forum in Davos, Switzerland. This was drafted, agreed and signed by ANTABIO among 85 companies and nine industry associations from across the global pharmaceutical, [...]
Antabio to attend the 34th Annual J.P. Morgan Healthcare Conference, 11–15 January 2016, San Francisco, CA, USA26 November 2015
Our CEO Dr. Marc Lemonnier will attend the J.P. Morgan 34th Annual Healthcare Conference which will take place 11–15 January 2016 in San Francisco, CA, USA. Marc is looking forward to meet with investors to discuss the Antabio portfolio and the exciting investment opportunity currently available at Antabio.
- 08 September 2015
The ICAAC Conference is the world’s premier international conference on antimicrobial agents and infectious diseases.
Antabio at the BIO One-on-One Partnering at the BIO International Convention 2015 in Philadelphia, June 15-18th26 May 2015
BIO One-on-One Partnering at the 2015 BIO International Convention is the largest venue for private company-to-company meetings in the world. Antabio’s partnering team will be available to meet during pre-scheduled 30-minute private one-on-one meetings. Send us your meeting request today !
ANTABIO receives €4 Million to develop new drugs to treat chronic infections in Cystic Fibrosis patients12 May 2015
Labège, France, May 12th 2015. Antabio SAS, a leading biopharmaceutical company in the field of antibacterial drug discovery, announced today that it has received a Wellcome Trust Seeding Drug Discovery Award to develop novel small molecule drugs for the treatment of chronic Pseudomonas infections in Cystic Fibrosis (CF) patients. CF [...]
Antabio is now a member of the newly launched Alliance of Biotechs of Europe innovating in Anti-Microbial Resistance, called the BEAM Alliance. This group of European biotechnology companies is committed to tackling the unique challenges facing the industry in the antibacterial field and currently regroups 34 companies from 10 European countries. [...]
Antabio awarded EUR 1 million funding from Bpifrance to support the discovery of New Gram-Negative Anti-Infective Agents09 April 2015
Labège and Maisons-Alfort, France, April 9th, 2015. Antabio SAS, a French antibacterial drug discovery company, and Bpifrance, announce that Antabio will receive EUR 1 million in funding to support its Antibiotic Adjuvant Factory (“The Factory”) dedicated to the discovery and development of new antibacterial treatments. These funds will be used [...]
- 10 February 2015
Organised by the French Senate and the ESSEC business school since 1999, Tremplin Entreprises is the most prestigious business plan contest for innovative companies in France. This is the third national award received by Antabio in less than a year, after the Septuors 2014 and the Concours Mondial de l’Innovation [...]
Antabio receives funding from the Midi-Pyrénées Region to support the expansion of its R&D capabilities02 December 2014
Antabio announces that it will receive EUR 90,000 in funding from the Midi-Pyrénées Region to support the expansion of its R&D capabilities in Labège. This funding will be awarded to Antabio under the Innovative SMEs Support Contracts scheme (“Contrat d’Appui PME Innovation”) operated by the French EU-Region Midi-Pyrénées. The award [...]
BioFIT attracts over 800 attendees from 30 countries among which top leaders from the pharma and biotech industry, academics and practitioners in technology transfer, intellectual property and licensing. Antabio’s partnering team will be available to meet during pre-scheduled 30-minute private one-on-one meetings. Send us your meeting request today !
- 23 July 2014
Antabio announces that it has been awarded the “Concours Mondial de l’Innovation 2030” Worldwide Innovation Challenge for its new discovery program focused on the treatment of chronic infections in cystic fibrosis (CF) patients. Antabio annonce que son projet de découverte de nouveaux traitements pour les patients atteints de mucoviscidose [...]
Antabio SAS presenting at the 8th Annual Fast-Track R&D Partnering Event in San Diego 23rd June 201403 June 2014
Antabio will be featured as a presenting company at the 8th Annual Fast-Track R&D Partnering with France (FTRD) seminar on 23rd June at the San Diego Convention Center from 11:00am to 5:00pm. Marc Lemonnier, CEO of Antabio, will be presenting the company and will answer questions on Antabio’s partnering strategy. If [...]
- 02 June 2014
Antabio’s profile is featured in a double-page article of the June 2014 special issue on infectious diseases of Nature Biopharma Dealmakers. The article describes the company’s history since its inception featuring some of its most innovative achievements, including the first successful round of crowdfunding applied to biotech start-up financing. The [...]
Antabio at the BIO One-on-One Partnering at the BIO International Convention 2014 in San Diego, June 23-26th28 May 2014
BIO One-on-One Partnering at the 2014 BIO International Convention is the largest venue for private company-to-company meetings in the world. Antabio’s partnering team will be available to meet during pre-scheduled 30-minute private one-on-one meetings. Scheduling begins June 2nd, send us your meeting request today !
- 16 May 2014
The 24th European Congress of Clinical Microbiology and Infectious Diseases in Barcelona, Spain, 10 – 13 May 2014.
The BIO Asia International Conference is an exclusive, customized partnering forum that brings together U.S. and European drug development companies with Asian biotech and pharmaceutical companies interested in research collaborations and licensing agreements.
Argenta and Antabio Announce Achievement of Milestone in their Anti-bacterial Drug Discovery Collaboration10 March 2014
Novel lead series of pan-metallo beta-lactamase inhibitors identified. Harlow, UK and Labège, France, 10th March 2014: Argenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to proof of concept, announced today that it has achieved a milestone with its collaboration partner Antabio in an [...]
Antabio announces achievement of milestone in the development of its metallo-carbapenemase inhibitor in collaboration with the Wellcome Trust27 February 2014
Antabio announced today that it has identified a lead series of pan-metallo beta-lactamase inhibitors that, in combination with carbapenems, restores antibacterial activity against life-threatening clinical isolates whilst exhibiting no toxicity or developmental issues.
Antabio awarded EUR 742,000 (USD 1,02 million) funding from Bpifrance to support the discovery of New Gram-Negative Anti-Infective Agents13 November 2013
Antabio and Bpifrance, the French public investment bank, announce that Antabio will receive EUR 742,000 (USD 1,02 million) in funding from Bpifrance to support the discovery, evaluation and development of new adjunctive antibiotic therapies. [...]
- 17 September 2013
Antabio is pleased to announce that the company has appointed Mr. Gordon Waldron as new non-executive member of its Strategic Advisory Board. Gordon was the Vice President and Chief Financial Officer of the antibacterial drug discovery company Novexel.
GTC’s Anti-Infectives Partnering & Deal Making is an infectious disease partnering and business development conference.
- 10 May 2013
The 23rd European Congress of Clinical Microbiology and Infectious Diseases will be held in Berlin from 27th to 30th April 2013.
- 20 March 2013
The meeting is the largest gathering of Biotech leaders and brings together over 1,100 biotechnology companies and related organizations over the course of 4 days.
- 18 February 2013
The 15th Annual Superbugs and Superdrugs Conference will be held in London, March 4th and 5th.
- 01 February 2013
Antabio, a French biopharmaceutical company, has received a €4.7 Million Wellcome Trust Seeding Drug Discovery Award to develop novel small molecule drugs for the treatment of life-threatening infections caused by multi-drug resistant Gram-negative bacteria. [...]
- 31 January 2013
Programme will focus on novel antibacterial agents.
07 February 2013
Harlow, UK and Labège, France – Argenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to proof of concept, announced today that it has signed a collaboration agreement with Antabio. Under the terms of the agreement, Argenta will provide medicinal chemistry, computer-aided drug design and ADME/PK services, together with its integrated drug discovery expertise, to assist Antabio in the identification of novel anti-bacterial agents and discovery of a development candidate that can be progressed into clinical trials. The collaboration is funded by a Wellcome Trust Seeding Drug Discovery award. [...]
- 14 December 2012
Antabio appoints Dr. Martin Everett as new Head of Biology.
- 01 November 2012
Ken Coleman, Jean-Denis Docquier, Roger Echols and Patrice Nordman join the SAB at Antabio.
Antabio and WiSEED announce the first successful round of crowdfunding applied to biotech start-up financing01 October 2012
Antabio, the biopharmaceutical antibacterial drug discovery company, and WiSEED, the French crowdfunding platform dedicated to innovative & technologic startups, announce the successful completion of their seed round of financing with a profitable exit of the initial small investors, a world premiere in the field of crowdfunding applied to biotech start-up [...]
- 20 September 2012
The ICAAC Conference is the world’s premier international conference on antimicrobial agents and infectious diseases.
- 15 September 2012
The new premises include 100 sqm of lab space and 150 sqm office space.
- 01 March 2012
Antabio appoints Delphine Ortega, MBA, as Business Partnering Manager of the company.
Antabio, the biopharmaceutical antibacterial drug discovery company, welcomes M. Christophe RICARD former CEO of the Swiss pharmaceutical group OM Pharma as its new investor. Under Mr RICARD’s leadership, OM Pharma developed and commercialized two record selling drugs aimed at preventing and treating bacterial infections, Broncho-Vaxom® and Uro-Vaxom®, prior to being [...]
- 08 September 2011
This French Biotech Tour is a partnering event focusing on infectious diseases in Boston.
- 04 July 2011
Antabio receives a grant from Oséo, the French public institution responsible for supporting innovation and growth of SME’s in France, to support its new discovery programme.
- 14 February 2011
Antabio, a biopharmaceutical expert in the fight against nosocomial bacterial infections, announces the raising of 309 K€ as a first part of its 1 million euro seed financing round. The young french start-up addresses a growing global health problem, recognized as n°1 priority by the World Health Organization. Antabio develops [...]
- 22 November 2010
Antabio relocates to Prologue Biotech bio-technopark, Labege. The new premises include 50 sqm of lab space and 20 sqm of office space.
- 01 June 2010
Antabio appoints Dr. David Davies as new Head of Medicinal Chemistry.
BioMedicalAlliance is a not for profit organization supporting the biopharma industry in the Midi-Pyrenees region (France).
- 01 December 2009
The Strategic Board supports and advises senior Management.
- 08 October 2009
The company is hosted and supported by the Midi-Pyrénées Incubator.
The Club Galaxie Award rewards the best ideas supporting the incorporation of an innovative company in the Midi-Pyrenees region. The Club Galaxie, founded in 2001, is composed of more than 78 executive leaders of small businesses, large corporations, industry and services as well as higher education and research entities in [...]